- Home
- RMM vs CCCC Comparison
RMM vs CCCC Comparison
Compare RMM & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- CCCC
- Stock Information
- Founded
- RMM 2019
- CCCC 2015
- Country
- RMM United States
- CCCC United States
- Employees
- RMM N/A
- CCCC N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- RMM Finance
- CCCC Health Care
- Exchange
- RMM Nasdaq
- CCCC Nasdaq
- Market Cap
- RMM 309.7M
- CCCC 405.6M
- IPO Year
- RMM N/A
- CCCC 2020
- Fundamental
- Price
- RMM $15.91
- CCCC $6.21
- Analyst Decision
- RMM
- CCCC Buy
- Analyst Count
- RMM 0
- CCCC 6
- Target Price
- RMM N/A
- CCCC $10.50
- AVG Volume (30 Days)
- RMM 66.5K
- CCCC 712.7K
- Earning Date
- RMM 01-01-0001
- CCCC 10-30-2024
- Dividend Yield
- RMM 7.33%
- CCCC N/A
- EPS Growth
- RMM N/A
- CCCC N/A
- EPS
- RMM 0.96
- CCCC N/A
- Revenue
- RMM N/A
- CCCC $29,378,000.00
- Revenue This Year
- RMM N/A
- CCCC $39.70
- Revenue Next Year
- RMM N/A
- CCCC N/A
- P/E Ratio
- RMM $15.55
- CCCC N/A
- Revenue Growth
- RMM N/A
- CCCC 83.26
- 52 Week Low
- RMM $12.32
- CCCC $1.06
- 52 Week High
- RMM $16.10
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- RMM 50.91
- CCCC 53.88
- Support Level
- RMM $15.70
- CCCC $6.02
- Resistance Level
- RMM $16.07
- CCCC $7.14
- Average True Range (ATR)
- RMM 0.20
- CCCC 0.37
- MACD
- RMM -0.02
- CCCC 0.10
- Stochastic Oscillator
- RMM 31.34
- CCCC 57.14
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.